Comparative Pharmacology
Head-to-head clinical analysis: AMNESTROGEN versus DIENESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTROGEN versus DIENESTROL.
AMNESTROGEN vs DIENESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
None Documented
None Documented
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Category C
Category C
Estrogen
Estrogen